Phase III-IV

© Getty Images

Finch halts biotherapeutic trial and axes 95 per cent of its staff

By Liza Laws

Finch Therapeutics announced its shock decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) yesterday (Jan 25) saying instead it will focus on ‘realizing the value of its intellectual property estate and...

(Iuliia Kanivets/iStock via Getty Images Plus)

CVS Health agrees to acquire Signify Health

By Jenni Spinner

With the purchase, the company is looking to advance its plans to connect with potential trial participants and spread awareness of study participation.

(royyimzy/iStock via Getty Images Plus)

People on the Move: September 2022

By Jenni Spinner

This month’s announcements of appointments, acquisitions, new hires, and other news include Standigm, Astellas Pharma, Trialbee, and other key companies.

Follow us

Product Innovations